Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
UTRECHT, The Netherlands, Nov. 10, 2016 -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday, November 17, 2016 at 11:20 PM GMT at the Waldorf Hilton in London, UK.
A live webcast of the Jefferies presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Merus N.V. Shelley Margetson – [email protected] +31 (0)30 253 8800 Argot Partners Kimberly Minarovich – [email protected] 1-212-600-1902
